Broadly neutralizing antibodies target a haemagglutinin anchor epitope

Abstract

Broadly neutralizing antibodies that target epitopes of haemagglutinin on the influenza virus have the potential to provide near universal protection against influenza virus infection 1 . However, viral mutants that escape broadly neutralizing antibodies have been reported 2,3 . The identification of broadly neutralizing antibody classes that can neutralize viral escape mutants is critical for universal influenza virus vaccine design. Here we report a distinct class of broadly neutralizing antibodies that target a discrete membrane-proximal anchor epitope of the haemagglutinin stalk domain. Anchor epitope-targeting antibodies are broadly neutralizing across H1 viruses and can cross-react with H2 and H5 viruses that are a pandemic threat. Antibodies that target this anchor epitope utilize a highly restricted repertoire, which encodes two public binding motifs that make extensive contacts with conserved residues in the fusion peptide. Moreover, anchor epitope-targeting B cells are common in the human memory B cell repertoire and were recalled in humans by an oil-in-water adjuvanted chimeric haemagglutinin vaccine 4,5 , which is a potential universal influenza virus vaccine. To maximize protection against seasonal and pandemic influenza viruses, vaccines should aim to boost this previously untapped source of broadly neutralizing antibodies that are widespread in the human memory B cell pool.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 100

1. 1.

   Paules CI, Marston HD, Eisinger RW, Baltimore D, Fauci AS. The pathway to a universal influenza vaccine. Immunity. 2017;47:599-603.

   Not in our library10.1016/j.immuni.2017.09.007

2. 2.

   Park JK, et al. Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model. Nat. Med. 2020;26:1240-1246.

   Not in our library10.1038/s41591-020-0937-x

3. 3.

   Guthmiller JJ, et al. First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Sci. Transl. Med. 2021;13:eabg453.

   Not in our library10.1126/scitranslmed.abg4535

4. 4.
   Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial · 2020

   No notice
5. 5.

   Nachbagauer R, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 2020;27:106-114.

   Not in our library10.1038/s41591-020-1118-7

6. 6.

   Ng S, et al. Novel correlates of protection against pandemic H1N1 influenza A virus infection. Nat. Med. 2019;25:962-967.

   Not in our library10.1038/s41591-019-0463-x

7. 7.

   Aydillo T, et al. Pre-existing hemagglutinin stalk antibodies correlate with protection of lower respiratory symptoms in flu-infected transplant patients. Cell Rep. Med. 2020;1:100130.

   Not in our library10.1016/j.xcrm.2020.100130

8. 8.

   Wrammert J, et al. Broadly cross-reactive antibodies dominate the human B cellresponse against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011;208:181-193.

   Not in our library10.1084/jem.20101352

9. 9.

   Andrews SF, et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci. Transl. Med. 2015;7:316ra192.

   Not in our library10.1126/scitranslmed.aad0522

10. 10.

    Dreyfus C, et al. Highly conserved protective epitopes on influenza B viruses. Science. 2012;337:1343-1348.

    Not in our library10.1126/science.1222908

11. 11.

    Benton DJ, et al. Influenza hemagglutinin membrane anchor. Proc. Natl Acad. Sci. USA. 2018;115:10112-10117.

    Not in our library10.1073/pnas.1810927115

12. 12.

    Ekiert DC, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011;333:843-850.

    Not in our library10.1126/science.1204839

13. 13.

    Friesen RH, et al. A common solution to group 2 influenza virus neutralization. Proc. Natl Acad. Sci. USA. 2014;111:445-450.

    Not in our library10.1073/pnas.1319058110

14. 14.

    Corti D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333:850-856.

    Not in our library10.1126/science.1205669

15. 15.

    DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 2016;126:605-610.

    Not in our library10.1172/jci84428

16. 16.

    He W, et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl Acad. Sci. USA. 2016;113:11931-11936.

    Not in our library10.1073/pnas.1609316113

17. 17.

    Guthmiller JJ, et al. Polyreactive broadly neutralizing B cells are selected to provide defense against pandemic threat influenza viruses. Immunity. 2020;53:1230-1244.e5.

    Not in our library10.1016/j.immuni.2020.10.005

18. 18.

    Sutton TC, et al. In vitro neutralization is not predictive of prophylactic efficacy of broadly neutralizing monoclonal antibodies CR6261 and CR9114 against lethal H2 influenza virus challenge in mice. J. Virol. 2017;91:e01603-17.

    Not in our library10.1128/jvi.01603-17

19. 19.

    Benton DJ, Gamblin SJ, Rosenthal PB, Skehel JJ. Structural transitions in influenza haemagglutinin at membrane fusion pH. Nature. 2020;583:150-153.

    Not in our library10.1038/s41586-020-2333-6

20. 20.

    Han J, et al. Polyclonal epitope mapping reveals temporal dynamics and diversity of human antibody responses to H5N1 vaccination. Cell Rep. 2021;34:108682.

    Not in our library10.1016/j.celrep.2020.108682

21. 21.

    Impagliazzo A, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015;349:1301-1306.

    Not in our library10.1126/science.aac7263

22. 22.

    Yassine HM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 2015;21:1065-1070.

    Not in our library10.1038/nm.3927

23. 23.

    Sun H, et al. Prevalent Eurasian avian-like H1N1 swine influenza virus with 2009 pandemic viral genes facilitating human infection. Proc. Natl Acad. Sci. USA. 2020;117:17204-17210.

    Not in our library10.1073/pnas.1921186117

24. 24.

    Caskey M, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487-491.

    Not in our library10.1038/nature14411

25. 25.

    Caskey M, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 2017;23:185-191.

    Not in our library10.1038/nm.4268

26. 26.

    Bar KJ, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 2016;375:2037-2050.

    Not in our library10.1056/nejmoa1608243

27. 27.

    Mendoza P, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561:479-484.

    Not in our library10.1038/s41586-018-0531-2

28. 28.

    Raymond DD, et al. Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Proc. Natl Acad. Sci. USA. 2018;115:168-173.

    Not in our library10.1073/pnas.1715471115

29. 29.

    Linderman SL, et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season. Proc. Natl Acad. Sci. USA. 2014;111:15798-15803.

    Not in our library10.1073/pnas.1409171111

30. 30.
    Playing Hide and Seek: How Glycosylation of the Influenza Virus Hemagglutinin Can Modulate the Immune Response to Infection · 2014

    No notice
31. 31.

    Pallesen J, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA. 2017;114:E7348-E7357.

    Not in our library10.1073/pnas.1707304114

32. 32.

    Dugan HL, et al. Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Sci. Transl. Med. 2020;12:eabd3601.

    Not in our library10.1126/scitranslmed.abd3601

33. 33.

    van der Lubbe JEM, et al. Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge. NPJ Vaccines. 2018;3:25.

    Not in our library10.1038/s41541-018-0063-7

34. 34.

    Cantisani R, et al. Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells. J. Immunol. 2015;194:1717-1725.

    Not in our library10.4049/jimmunol.1400623

35. 35.

    Liang F, et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med. 2017;9:eaal2094.

    Not in our library10.1126/scitranslmed.aal2094

36. 36.

    Khurana S, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2010;2:15ra15.

    Not in our library10.1126/scitranslmed.3000624

37. 37.

    Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010;328:1272-1275.

    Not in our library10.1126/science.1187816

38. 38.

    Guthmiller JJ, Dugan HL, Neu KE, Lan LY, Wilson PC. An efficient method to generate monoclonal antibodies from human B cells. Methods Mol. Biol. 2019;1904:109-145.

    Not in our library10.1007/978-1-4939-8958-4_5

39. 39.

    Wrammert J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453:667-671.

    Not in our library10.1038/nature06890

40. 40.

    Smith K, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 2009;4:372-384.

    Not in our library10.1038/nprot.2009.3

Cited by papers we hold 1

• Functional antibodies exhibit light chain coherence · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.